Insider Selling: HealthEquity (NASDAQ:HQY) EVP Sells $223,630.00 in Stock

HealthEquity, Inc. (NASDAQ:HQY) EVP Michael Henry Fiore sold 2,354 shares of HealthEquity stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $95.00, for a total transaction of $223,630.00. Following the transaction, the executive vice president directly owned 52,244 shares of the company’s stock, valued at approximately $4,963,180. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Henry Fiore also recently made the following trade(s):

• On Thursday, July 2nd, Michael Henry Fiore sold 2,470 shares of HealthEquity stock. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00.
• On Friday, May 29th, Michael Henry Fiore sold 3,142 shares of HealthEquity stock. The stock was sold at an average price of $95.00, for a total transaction of $298,490.00.

HealthEquity Stock Up 3.8%

Shares of NASDAQ:HQY opened at $98.69 on Friday. The firm has a market capitalization of $8.25 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 1.60 and a beta of 0.21. The business has a 50 day simple moving average of $88.50 and a two-hundred day simple moving average of $84.69. HealthEquity, Inc. has a 1 year low of $72.76 and a 1 year high of $105.96. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.13. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The firm had revenue of $354.64 million for the quarter, compared to the consensus estimate of $352.02 million. HealthEquity’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. On average, equities analysts predict that HealthEquity, Inc. will post 3.92 EPS for the current year.

Institutional Trading of HealthEquity

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wasatch Advisors LP grew its holdings in HealthEquity by 10.5% during the 2nd quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after acquiring an additional 757,801 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of HealthEquity by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock worth $201,685,000 after purchasing an additional 5,671 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of HealthEquity by 13.7% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock worth $178,864,000 after purchasing an additional 235,794 shares during the period. William Blair Investment Management LLC purchased a new stake in shares of HealthEquity in the 4th quarter worth approximately $169,956,000. Finally, AQR Capital Management LLC boosted its stake in shares of HealthEquity by 59.3% during the third quarter. AQR Capital Management LLC now owns 1,764,268 shares of the company’s stock valued at $167,200,000 after purchasing an additional 656,820 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HQY has been the subject of several research analyst reports. Citizens Jmp lifted their target price on HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft upped their price target on shares of HealthEquity from $120.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Royal Bank Of Canada lifted their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. Wells Fargo & Company set a $111.00 price objective on shares of HealthEquity in a research report on Monday, June 1st. Finally, Weiss Ratings upgraded shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.57.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.